List of Contract Manufacturing Companies in China - 18

Chongqing Sintaho Pharmaceutical Co., Ltd. takes chemistry as the core, located at Chongqing International Biological City in China, jointly founded by Chongqing Taihao Pharmaceutical Co., Ltd. (established in 2004) and a US new-drug enterprise in July 2016. With 260+ employees integrated with R&D, production, regulatory affairs, and marketing, Sintaho commits itself to the global market, particularly the US, EU, and China. Sintaho specializes in chemosynthetic APIs (therapeutic areas mainly contain oncology, nervous system and metabolic diseases), with a product portfolio ranging from small molecule APIs, ADC compounds (linkers and payloads) to polypeptides, also provides CDMO services of cytotoxic and OEB4/5 grade APIs. Sintaho contributes to being the most dependable partner for global pharmaceutical companies.

Established in 1998 in Shenzhen, China, Hepalink is a leading multinational biopharmaceutical company dual-listed in Hong Kong and mainland China, with its core business in heparin industrial chain, large molecule biologics CDMO services, and the research, development, and commercialization of innovative drugs. These three synergistic business segments are driven by the mission of addressing patients' unmet medical needs and bringing safe and effective therapies and services to patients around the world.

Jiangsu Hillgene BioPharma is a leading CDMO platform for cell therapeutics. Our shareholders include China SME Development Fund, Guokejiahe Fund, Haier Capital, Huapont life science, China Capital Management, etc. The company is headquartered in Wuzhong District of Suzhou, the beautiful shore of Taihu Lake, with a registered capital of 100 million RMB. At present, a nationwide network of production bases has been formed initially, consisting of the headquarters in Suzhou (10000m2 GMP facility constructed) and the production base in Shenzhen (8000m2 GMP facility under construction). Meanwhile, the production base in North Carolina that is under construction contributes to the global layout     Hillgene focuses on cell therapeutics' and  particular plasmid production platforms, suspended and serum-free culture of viruses, and fully enclosed process development of cells, providing one-stop services from discovery to product delivery. We have helped several partners successfully develop drugs including CAR-T, TCR-T, and stem cells. And we are dedicated to pushing more projects to a new milestone quickly and bringing more cell therapy drugs into the market to let patients enjoy the products. Cell therapy innovation inspired.

HitGen Inc. (SSE: 688222.SH), founded in 2012, is headquartered in Chengdu, China, with subsidiaries in Cambridge, UK and Houston, USA. HitGen is committed to building a world-class innovative biopharmaceutical enterprise and contributing to the better life and health of mankind. Engaged in the discovery and optimization of small molecules and nucleic acid drugs, HitGen dedicates itself to cultivating an internationally leading drug discovery and optimization system centered on four key technology platforms, including DNA-encoded library technology (including DEL design, synthesis and screening, and application expansion), fragment-based drug discovery and structure-based drug design technologies (FBDD/SBDD), synthetic therapeutic oligonucleotide technology (STO), and targeted protein degradation technology (TPD). It provides new molecular entities (NMEs) at different stages of research and development for the pharmaceutical industry, through its diversified business models including research and development services, out-licensing of projects at different R&D stages, and new drug launches in the long term, with an aim to address unmet clinical needs with innovative therapeutic solutions. As a leader in the field of DEL technology, HitGen has been committed to the development, application and improvement of DEL technology since its establishment. HitGen has approximately 20 in-house drug discovery projects at different stages of research and development, among which 4 have obtained IND approvals and entered into clinical trials. HitGen is in collaboration with pharmaceutical, biotech and chemical companies, foundations and research institutes in the Americas, Asia, Europe, Africa, and Oceania. For more information, please call +86-28-85197385, +1-508-840-9646 or visit www.hitgen.com. For business development: bd@hitgen.com

Kunshi Biotechnology is a privately held company located in Kunshan City, Jiangsu Province. The company is involved in high-level research and production in the biotechnology field.

Mido (Nanjing) Biotechnology Co., Ltd. is the first molecular imaging pharmaceutical research and development outsourcing (MI-CRO) company in China. The company leverages the world’s most advanced radiolabeling and in vivo molecular imaging technologies to provide domestic and international clients with comprehensive solutions and outsourced technical services for new drug R&D, including drug screening, biodistribution, pharmacokinetic research, and pharmacodynamic evaluation. Its business spans translational research from nude mice, rats, and monkeys to humans, focusing on major diseases such as cancer, coronary heart disease, Alzheimer’s disease, Parkinson’s disease, epilepsy, rheumatism, and diabetes, as well as cutting-edge fields involving receptors, genes, and stem cells. It explores disease mechanisms, develops diagnostic and therapeutic drugs, and evaluates therapeutic outcomes. PET molecular imaging offers unique advantages—such as in vivo imaging, dynamic quantification, self-control, and continuous observation—that significantly shorten the drug development cycle, reduce the risk of failure, and accelerate the introduction of new drugs to the market. 米度（南京）生物技术有限公司是国内首家分子影像医药研发外包（MI-CRO）企业。公司利用世界先进的放射标记示踪（Radiolabeling）和活体分子显像（Molecular imaging）技术为海内外客户提供药物筛选、生物分布、药代动力学研究、药效学评价等新药研发整体解决方案和外包技术服务，业务贯穿从裸（小）鼠、大鼠、猴子到人体的转化研究，重点针对肿瘤、冠心病、老年痴呆、帕金森、癫痫、风湿免疫、糖尿病等重大疾病以及受体、基因、干细胞等前沿研究领域，探寻疾病机理、开发诊疗药物、评价治疗效果。PET 分子影像具有活体显像、动态定量、自身对照、连续观察等突出优点，大大缩短药物研发周期、降低失败风险、加快新药上市。

Founded in 2005, Porton Pharma Solutions Ltd. is an internationally recognized pharmaceutical contract development and manufacturing organization (CDMO) in enabling our global clients to optimize drug development and manufacturing. We provide customer development and manufacturing services for small molecule, Large molecule and Gene and Cell Therapies from pre-clinical to commercialization. As of June 30, 2023, we have a proven record for the delivery of more than 2600 projects and established cooperation with more than 800 global clients. With our 5000+ skilled employees working across 20+ sites around the globe, Porton is committed to becoming the most open, innovative and reliable pharmaceutical service platform in the world and enabling the public's early access to good medicines. Porton is publicly listed on the Shenzhen Stock Exchange (Ticker: 300363). With over 5000 customer-centric employees, operations and commercial offices across the US, EU and China, Porton Pharma Solutions/J-Star Research provides global pharmaceutical companies with innovative, reliable and end-to-end process R&D and GMP manufacturing services across small molecule APIs, TIDES, biologics and Gene & Cell Therapies. We focus on the customer and have been recognized through awards by industry forums and global pharmaceutical companies for our process innovation, supply chain performance, and compliance with global Quality and EHS standards. We constantly strive for excellence and enable the public's early access to good medicines.

Sanyou Biopharmaceuticals Co., Ltd. is a world-leading high-tech biotechnology enterprise focusing on R&D and services of innovative biologic drugs. Sanyou is committed to bridge drug R&D and all-life-cycle manufacture supply chain, and has built the 4C business patterns that integrate "differentiated CRO, integrated CDO, innovative CPO and characteristic CRS”, to accomplish the mission “to make the R&D easy for innovative biologics”.

An Unique TIDEs Platform with Cutting Edge Technologies As an industry leader in therapeutic peptides, Sinopep stands as the exclusive API supplier for Albuvirtide and Lanreotide 505b2—two of the top five in-demand peptide products. We are also the global leader in supplying Semaglutide, Tirzepatide, and Liraglutide, dominating the market in export quantity. Sinopep consistently delivers the highest quality peptide APIs, supported by comprehensive documentation that meets stringent global standards. Our advanced process development and manufacturing technologies ensure efficient production with high yields and some of the largest batch sizes in the industry. Additionally, Sinopep excels in providing efficient, flexible, and high-quality end-to-end CRDMO services across multiple modalities, including peptides, oligonucleotides, small molecules, and related synthetic conjugates. This makes Sinopep a trusted partner in the pharmaceutical and healthcare industries worldwide.

SinoTherapeutics is a specialty pharma focus on the R&D, registration, manufacture and commercialization of complex generic products as well as innovative formulation products (505B2). The company aims to achieve commercialize its product globally, and to provide cost-effective high-quality products to international markets

The mission of the company is to develop innovative diagnostic reagents, cellular therapeutics technologies and engineered cell products to help

TransGen Biotech Co., Ltd is a researcher and manufacturer of molecular and cellular biology products.

VectorBuilder offer gene delivery technologies. VectorBuilder offers a full spectrum of gene delivery solutions covering virtually all research and clinical needs from bench to bedside

As a global company with operations across Asia, Europe, and North America, WuXi AppTec provides a broad portfolio of R&D and manufacturing services that enable the global pharmaceutical and life sciences industry to advance discoveries and deliver groundbreaking treatments to patients. Through its unique business models, WuXi AppTec’s integrated, end-to-end services include chemistry drug CRDMO (Contract Research, Development and Manufacturing Organization), biology discovery, preclinical testing and clinical research services, advanced therapies CTDMO (Contract Testing, Development and Manufacturing Organization), helping customers improve the productivity of advancing healthcare products through cost-effective and efficient solutions. WuXi AppTec received an AA ESG rating from MSCI for the third consecutive year in 2023 and its open-access platform is enabling more than 6,000 customers from over 30 countries to improve the health of those in need – and to realize the vision that "every drug can be made and every disease can be treated."

Dongguan Xinyi Biotechnology Co., Ltd. which is established in 2022 in dongguan, is a cosmetics company specializing in production, sales and marketing With first-class production technology and equipment, the company is committed to the research and development . production and sales of high-tech cosmetics, as well as the directional application of traditional Chinese medicine plant raw materials, biological extraction raw materals and functional raw materials. We have cooperated with Australia, Canada and other foreign cooperative manufacturers and professional research institutions to carry out project cooperation, to introduce of advanced management system and cutting-edge science and technology, to develop of domestic first-class, cost-effective personal care products.

Zhejiang Medicine Co.,Ltd founded in 1954. currently has nine major subsidiaries and two research units.The company has more than 6,800 employees, including more than 2,500 professional and technical personnel, who account for more than 37% of the company’s total number of employees. Zhejiang Medicine performs the specialized and large-scale production of fat-soluble vitamins, retinoids, quinolone antibiotics, anti-resistance antibiotics, and other products. The company's leading products, including its synthetic Vitamin E, natural Vitamin E, β-carotene,Lutein, Fish oil(Omega-3) etc.,

公司的主营业务为特色原料药、医药中间体的研发、生产和销售，以及为客户提供定制加工和研发业务。产品具有手性结构多、研发难度大、技术壁垒高、生产工艺独特等特点。公司是高新技术企业，被认定为“省级高新技术企业研究开发中心”、“省级企业研究院”，公司拥有院士工作站、博士后工作站、博士后创新实践基地等优秀的研发平台，与诸多高校、研究所保持良好的研发合作关系。